Article Text

Download PDFPDF
Use of PlasmaJet for Peritoneal Carcinomatosis in Ovarian Cancer
  1. Enrico Panuccio, MD,
  2. Karin Leunen, MD, PhD,
  3. Els Van Nieuwenhuysen, MD,
  4. Patrick Neven, MD, PhD,
  5. Sandrina Lambrechts, MD and
  6. Ignace Vergote, MD, PhD, FACS, FSPS
  1. * Division of Gynecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, KU Leuven, Leuven, European Union; and
  2. Department of Gynecology and Obstetrics, University of Turin, Mauriziano Hospital, Turin, Italy.
  1. Address correspondence and reprint requests to Ignace Vergote, MD, PhD, FACS, FSPS, Division of Gynecologic Oncology, Herestraat 49, B-3000 Leuven, European Union. E-mail: Ignace.vergote{at}uzleuven.be.

Abstract

Objective This study aimed to assess the role and complications of extensive cytoreduction with PlasmaJet (Plasma Surgical, Roswell, Ga) in ovarian cancer with peritoneal carcinomatosis.

Materials All patients undergoing primary, secondary, or interval debulking surgery for ovarian cancer and treated with PlasmaJet between October 2013 and February 2015 were analyzed.

Results Nineteen patients were enrolled. The median operative time was 270 minutes, median blood loss was 700 mL, and median length of stay was 9 days. In all patients, complete resection of all macroscopic disease was achieved.

We used PlasmaJet to remove peritoneal carcinomatosis on the abdominal peritoneum, intestinal mesentery, bowel serosa, and diaphragmatic region. Overall, we treated 66 organs with PlasmaJet in our series. No bowel or urological fistulas were observed. According to the Clavien-Dindo classification, 13 adverse events were recorded at grade 2 or lesser. We observed only 1 grade 3 adverse event. No postoperative mortality was recorded.

Conclusions In our series, the PlasmaJet seems to be an efficient device for tumor ablation or dissection to obtain complete resection of all macroscopic disease in patients with peritoneal carcinomatosis.

  • PlasmaJet
  • Peritoneal carcinomatosis
  • Surgery
  • Ovarian cancer

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.